Hidoc Dr | Medical Learning App for Doctors

Today's Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Published Date: 20 Oct 2026

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

Published Date: 20 Oct 2026

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

Published Date: 20 Oct 2026

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Published Date: 20 Oct 2026

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

Published Date: 20 Oct 2026

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

Published Date: 20 Oct 2026

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Published Date: 20 Oct 2026

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Published Date: 20 Oct 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Published Date: 20 Oct 2026

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Published Date: 20 Oct 2026

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Knowledge Hub

Oncology

Smart Oncology Infusion Chairs With Integrated Treatment Data: Transforming Chemotherapy Delivery and Patient Monitoring

Review of smart oncology infusion chairs with integrated data systems improving cancer care delivery.

Oncology

Intracellular Nanobody Therapeutics: Mechanisms, Clinical Relevance, and Emerging Applications

Review of intracellular nanobody therapeutics for targeting undruggable intracellular disease drivers.

Oncology

Screening for Occult Leptomeningeal Disease Through Cerebrospinal Fluid Tumor DNA Analysis

Review of CSF tumor DNA analysis for early detection of occult leptomeningeal disease in oncology.

Oncology

Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance

Review of early neurovascular biomarker surveillance in preventing immune effector cell-associated neurotoxicity for clinicians.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Knowledge Hub

Smart Oncology Infusion Chairs With Integrated Treatment Data: Transforming Chemotherapy Delivery and Patient Monitoring

Intracellular Nanobody Therapeutics: Mechanisms, Clinical Relevance, and Emerging Applications

Screening for Occult Leptomeningeal Disease Through Cerebrospinal Fluid Tumor DNA Analysis

Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance

Screening for Treatment-Related Sarcopenia in Cancer Care

Tissue Reconstruction After Extensive Cancer Surgery: Advances, Challenges, and Clinical Considerations

Therapeutic RNA Vaccines for Melanoma

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Knowledge Hub

Smart Oncology Infusion Chairs With Integrated Treatment Data: Transforming Chemotherapy Delivery and Patient Monitoring

Intracellular Nanobody Therapeutics: Mechanisms, Clinical Relevance, and Emerging Applications

Screening for Occult Leptomeningeal Disease Through Cerebrospinal Fluid Tumor DNA Analysis

Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance

Screening for Treatment-Related Sarcopenia in Cancer Care

Tissue Reconstruction After Extensive Cancer Surgery: Advances, Challenges, and Clinical Considerations

Therapeutic RNA Vaccines for Melanoma

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views